Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Youcare Pharmaceutical Group Co., Ltd. (688658.SS)
Beijing, CN
Youcare Pharmaceutical Group Co., Ltd. operates across the entire pharmaceutical value chain, from initial research and development to the manufacturing, distribution, and sale of its medicinal products. The company provides a diverse range of drug formulations, including injectables, tablets, capsules, and granules. Its extensive product portfolio addresses numerous therapeutic areas, such as anti-infectives (including antibiotics, antibacterials, and antivirals), gastrointestinal health, topical treatments, diabetes management (hypoglycemic agents), anti-hepatitis, anti-tumor therapies, cardiovascular and cerebrovascular care, and immunomodulators. Established in 1988, Youcare Pharmaceutical Group Co., Ltd. maintains its headquarters in Beijing, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.94% | -4.71% | -9.08% | -13.41% | -28.00% | -21.19% | +27.93% | -28.81% | -21.81% | -43.68% | -43.68% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-35.3% Q1'26: -3.7% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-310.7% Q1'26: +36.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+3.7% Q1'26: +3.3% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-9.3% Q1'26: -4.7% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-8.7% ★ Q1'26: -4.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+2.6% ★ Q1'26: +5.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-23.05× Q1'26: -5.39× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
4.97B
est: 5.08B (-2.2%)
|
4.54B
est: 5.58B (-18.6%)
|
4.20B
est: 4.24B (-1.1%)
|
3.78B
est: 4.05B (-6.6%)
|
2.45B
est: 3.55B (-31.0%)
|
3.73B
3.73B – 3.73B
+5.3% YoY
|
4.10B
4.10B – 4.10B
+9.9% YoY
|
| EBITDA |
769.20M
est: 579.00M (+32.8%)
|
509.45M
est: 636.79M (-20.0%)
|
405.86M
est: 484.11M (-16.2%)
|
371.85M
est: 363.63M (+2.3%)
|
-32.03M
est: 318.46M (-110.1%)
|
335.34M
335.34M – 335.34M
+5.3% YoY
|
368.39M
368.39M – 368.39M
+9.9% YoY
|
| EBIT |
633.92M
est: 392.79M (+61.4%)
|
355.31M
est: 431.99M (-17.8%)
|
237.72M
est: 328.41M (-27.6%)
|
175.89M
est: 174.80M (+0.6%)
|
-227.99M
est: 153.08M (-248.9%)
|
161.20M
161.20M – 161.20M
+5.3% YoY
|
177.09M
177.09M – 177.09M
+9.9% YoY
|
| Net Income |
545.32M
est: 552.64M (-1.3%)
|
335.18M
est: 475.59M (-29.5%)
|
184.80M
est: 217.80M (-15.2%)
|
123.72M
est: 301.00M (-58.9%)
|
-262.39M
est: 63.46M (-513.5%)
|
181.31M
181.31M – 181.31M
+185.7% YoY
|
394.35M
394.35M – 394.35M
+117.5% YoY
|
| SGA |
2.55B
est: 2.41B (+5.6%)
|
2.21B
est: 2.65B (-16.8%)
|
1.98B
est: 2.02B (-1.9%)
|
1.52B
est: 1.77B (-13.9%)
|
759.45M
est: 1.55B (-51.0%)
|
1.63B
1.63B – 1.63B
+5.3% YoY
|
1.79B
1.79B – 1.79B
+9.9% YoY
|
| EPS |
1.21
est: 1.24 (-2.7%)
|
0.74
est: 1.07 (-30.8%)
|
0.41
est: 0.49 (-16.3%)
|
0.28
est: 0.67 (-58.2%)
|
-0.59
est: 0.14 (-521.4%)
|
0.40
0.40 – 0.40
+185.7% YoY
|
0.87
0.87 – 0.87
+117.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-25 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 25.9K | 0.46% |
| 2 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 84.8K | 0.39% |
| 3 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 70.4K | 0.29% |
| 4 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 28.6K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Fei Yu | MD, GM & Director | — | male |
| Genshen Song | Deputy GM & Director | — | male |
| Jiang Zhang | Deputy GM & Director | — | male |
| Lei Yang | Deputy General Manager of R&D Center | — | male |
| Mengyang Hao | Board Secretary | — | male |
| Qibo Zhang | Deputy General Manager & Director | — | male |
| Xia Wang | Deputy General Manager | — | female |
| Xuping Yuan | Deputy General Manager | — | female |
| Yan Liu | Financial Director & Chief Financial Officer | — | female |
| Yusheng Li | Deputy General Manager of Anhui Natural Pharmaceuticals | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688658.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
